| Title: | Genome-wide association study on pharmacological outcomes of musculoskeletal pain in UK Biobank |
| Journal: | The Pharmacogenomics Journal |
| Published: | 16 Aug 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37587271/ |
| DOI: | https://doi.org/10.1038/s41397-023-00314-x |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 9750
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
The pharmacological management of musculoskeletal pain starts with NSAIDs, followed by weak or strong opioids until the pain is under control. However, the treatment outcome is usually unsatisfying due to inter-individual differences. To investigate the genetic component of treatment outcome differences, we performed a genome-wide association study (GWAS) in ~23,000 participants with musculoskeletal pain from the UK Biobank. NSAID vs. opioid users were compared as a reflection of the treatment outcome of NSAIDs. We identified one genome-wide significant hit in chromosome 4 (rs549224715, P = 3.88 × 10−8). Suggestive significant (P < 1 × 10−6) loci were functionally annotated to 18 target genes, including four genes linked to neuropathic pain processes or musculoskeletal development. Pathway and network analyses identified immunity-related processes and a (putative) central role of EGFR. However, this study should be viewed as a first step to elucidate the genetic background of musculoskeletal pain treatment.</p>
4 Authors
- Song Li
- Geert Poelmans
- Regina L. M. van Boekel
- Marieke J. H. Coenen
1 Application
| Application ID | Title |
|---|---|
| 52524 | Genetic basis of adverse drug reactions |
Enabling scientific discoveries that improve human health